Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780239 | 0.89 | PDE10A (0.33) | KCNH2PDE10A | |
| SCHEMBL5779996 | 0.86 | KCNH2 (0.34) | KCNH2ALDH1A1 | |
| SCHEMBL4766440 | 0.85 | BMPR1B (0.33) | KCNH2BMPR1BACVR1BTGFBR1ACVRL1 | |
| SCHEMBL5779131 | 0.85 | PDE10A (0.31) | ALDH1A1SMN1; SMN2PDE10A | |
| SCHEMBL5780338 | 0.85 | MAPK14 (0.30) | — | |
| SCHEMBL4771769 | 0.85 | HSP90AA1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5778886 | 0.84 | HCRTR1 (0.31) | — | |
| SCHEMBL8295703 | 0.84 | PDE4A (0.32) | BMPR1BACVR1BTGFBR1ACVRL1ACVR1 | |
| SCHEMBL4764107 | 0.83 | ALDH1A1 (0.33) | KCNH2ALDH1A1PDE10A | |
| SCHEMBL5783478 | 0.83 | DHODH (0.33) | BMPR1BACVR1BTGFBR1ACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560822-B1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORP (US) | 2006-08-09 | — | — | EP | claimed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | claimed |
| EP-1560822-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | Neurogen Corporation (US) | 2005-08-10 | — | — | EP | claimed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | claimed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | claimed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1880998-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1648899-B1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1560822-B1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORP (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1648899-A2 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1560822-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | Neurogen Corporation (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012306-A2 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | disclosed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | GABRA1, GABRA4, GABRA3 | KCNH2 1174/4885BMPR1B 1753/4885ACVR1B 600/4885 |
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | GABRA3, GABRA1, GABBR1 | KCNH2 586/4885BMPR1B 1305/4885ACVR1B 965/4885 |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | GABRA3, GABRA1, GABBR1 | KCNH2 586/4885BMPR1B 1305/4885ACVR1B 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.